Ventyx Biosciences, Inc. (VTYX) Monday announced that the Phase 2 trial of allosteric TYK2 inhibitor VTX to treat moderately to severely active Crohn's disease failed to meet the primary endpoint. Currently, shares are falling more than 24.40 percent at $2.24 on a volume of 1,466,064, compared to Friday's closing of $2.95. The biopharmaceutical company said the primary endpoint was the change in the mean Crohn's disease activity index score from baseline to Week 12. The Phase 2 trial enrolled 109 participants randomized to one of two VTX958 doses for a 12-week induction treatment period.
The company intends to conduct further analyses of the data to better understand the discordance between symptomatic and endoscopic response data. At this time, Ventyx does not anticipate conducting additional clinical trials of VTX958 with internal resources.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.